Over the last 40 years, we — as a society — have seen incredible progress in the way illnesses, such as cancer are treated. We owe these advances to medical research and the millions of patients who have volunteered to participate in clinical trials. As one of five Roche global pharmaceutical Product Development sites, we contribute to all phases of clinical trial development, including overseeing clinical studies in Canada, the US and around the world.
In 2018, Roche invested over $57 million in clinical research in Canada through 442 Roche-sponsored clinical trial sites, which offer people with a variety of medical conditions an opportunity to participate in the development of potential new treatment options.
Clinical trials are an integral part of a new drug or diagnostic discovery and development process as they provide evidence about the safety and efficacy of a medicine or diagnostic. They also provide important information about cost-effectiveness, clinical value, and impact on a patient’s quality of life.
Advances in our understanding of human biology bring us closer to discovering more precise, personalized approaches to treating diseases. As a country with a rich ecosystem and history of research excellence, Canada has the opportunity to play a pivotal leadership role in advancing the future of healthcare. Driving innovation-first policies will ensure this leadership and enhance our ability to compete for clinical research investments on a global stage.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. @RocheCanada